Baltimore Washington Financial Advisors Inc. Invests $465,000 in Amgen Inc. $AMGN

Baltimore Washington Financial Advisors Inc. bought a new position in Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,648 shares of the medical research company’s stock, valued at approximately $465,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Intellectus Partners LLC raised its position in Amgen by 226.3% during the 3rd quarter. Intellectus Partners LLC now owns 3,224 shares of the medical research company’s stock valued at $910,000 after purchasing an additional 2,236 shares during the last quarter. Foster Dykema Cabot & Partners LLC grew its position in shares of Amgen by 82.6% in the 3rd quarter. Foster Dykema Cabot & Partners LLC now owns 767 shares of the medical research company’s stock worth $216,000 after buying an additional 347 shares during the last quarter. Guardian Capital LP increased its stake in shares of Amgen by 7.4% during the third quarter. Guardian Capital LP now owns 25,366 shares of the medical research company’s stock valued at $7,158,000 after buying an additional 1,753 shares during the period. LOM Asset Management Ltd increased its stake in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after buying an additional 30 shares during the period. Finally, Integrity Advisory Solutions LLC bought a new position in shares of Amgen during the third quarter valued at approximately $1,017,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of Amgen stock opened at $369.53 on Friday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The firm has a market capitalization of $199.20 billion, a P/E ratio of 25.97, a P/E/G ratio of 3.65 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The business has a fifty day simple moving average of $353.26 and a two-hundred day simple moving average of $322.43.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AMGN. Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. BMO Capital Markets raised their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Morgan Stanley increased their price target on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $354.17.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.